Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT -0.67%31 Cash-to-Debt is 3.24 as of Jun. 2026, which is 80% below its 10-year median of 16.44. GuruFocus rates COGT with a GF Score™ of 31/100. The stock has 4 warning signs investors should review. Among 1,395 Biotechnology companies, Cogent Biosciences ranks worse than 60.14% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cogent Biosciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 3.24.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cogent Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Cogent Biosciences's Cash-to-Debt or its related term are showing as below:
COGT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 3.24 Med: 16.44 Max: No Debt
Current: 3.24
During the past 11 years, Cogent Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 3.24. And the median was 16.44.
COGT's Cash-to-Debt is ranked worse than 60.14% of 1395
companies
in the Biotechnology industry
Industry Median: 7.17
vs COGT: 3.24
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Cogent Biosciences Cash-to-Debt Related Terms
Cogent Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Cogent Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogent Biosciences (COGT) has a Cash-to-Debt of 3.24 as of Jun. 2026. This is 80% below median its historical median of 16.44. Over the past decade, Cogent Biosciences' Cash-to-Debt has ranged from 3.24 to 10,000.00. According to the industry distribution chart, Cogent Biosciences ranks #839 out of 1395 companies in the Biotechnology industry, placing it in the top 60.1%.
Is Cogent Biosciences' Cash-to-Debt too high?
Cogent Biosciences' current Cash-to-Debt of 3.24 is 80% below median its 10-year median of 16.44. Over the past 10 years, this metric has ranged from a low of 3.24 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.17. Cogent Biosciences' value of 3.24 is 54.8% below this industry median. Based on the distribution chart, Cogent Biosciences ranks #839 out of 1395 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cogent Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Cash-to-Debt compare to ORKA and MIRM?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #839 out of 1395 companies for Cash-to-Debt. This places Cogent Biosciences in the lower half of its industry. The industry median Cash-to-Debt is 7.17. Cogent Biosciences' value of 3.24 is 54.8% below this benchmark. Historically, Cogent Biosciences' own Cash-to-Debt has ranged from 3.24 to 10,000.00 over the past decade. While the company's 10-year median is 16.44 vs. the industry median of 7.17, Cogent Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.17, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cogent Biosciences's current Cash-to-Debt of 3.24 is 54.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cogent Biosciences's current Cash-to-Debt is 3.24, which is 80% below median its own 10-year median of 16.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Cash-to-Debt of 3.24. The current Cash-to-Debt is 3.24, which is 80% below median its 10-year median of 16.44 and 54.8% below the Biotechnology industry median of 7.17. Cogent Biosciences' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Cash-to-Debt is 3.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
31GF Score
Get the complete analysis for COGT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
